Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze EW Edwards Lifesciences Corporation. Please read: https://finlab.finance/en/setup?stock=EW

No install, open FinLab Studio

EW

Edwards Lifesciences Corporation Healthcare As of 2026-07-31 Updated daily after market close

strong quality, premium valuation.

1 active signal
Filed revenue acceleration
This page refreshes daily after the close. Add Edwards Lifesciences Corporation to your watchlist to track signal changes on your next visit.
Valuation 28Quality 74Growth 48Momentum 58Risk / liquidity 86

Is Edwards Lifesciences Corporation a buy? Fundamentals and valuation first

  • Quality is top-tier. Operating margin ranks above roughly 83% of the liquid US common-stock universe. TTM ROE is about 9.7%.

  • Valuation is expensive. TTM P/E is in the 90th percentile, above most peers.

  • Recent volatility is comparatively low. 60-day annualized volatility is in the 24th percentile. Average 20-day dollar volume is about $454.2M.

  • Signals are active now. Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 14.550315737629948%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

13 historical occurrences (since 2019-04-26)
Average forward return after Filed revenue acceleration。20-day: Win 38.5%, Sample 13, Median -0.88%, Excess +0.04%, Beat mkt rate 69.2%；60-day: Win 45.5%, Sample 11, Median -0.24%, Excess -0.25%, Beat mkt rate 45.5%；120-day: Win 60%, Sample 10, Median +0.76%, Excess +3.31%, Beat mkt rate 70%

120 days after: historical avg +3.86%

20-day -2.95%
60-day -0.38%
120-day +3.86%
20-day
60-day
120-day
Win
38.5%
45.5%
60%
Sample
13
11
10
Median
-0.88%
-0.24%
+0.76%
Excess
+0.04%
-0.25%
+3.31%
Beat mkt rate
69.2%
45.5%
70%

Over 10 occurrences, 120-day forward avg gained 3.86%, beat the market by 3.31 pts; win rate 60%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 595+5.2% +6.6% 63.7% -15.4%
20-40 325-3.6% -11.5% 25.2% -20.2%
40-60 185-19.1% -24.6% 15.1% -15.7%
60-80 You are here50+15.5% +32% 72% +7.8%
80-100 222+27.3% +33.1% 82% +11.1%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 49.47, placing it in the 72.5 own-history percentile, inside the 60-80 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
-1.4%
Win rate 56.8% Excess -9.8%
414d
-9.6%
Win rate 31.4% Excess -10.7%
245d
Now
+14.8%
Win rate 92.7% Excess +1.8%
205d
60-day momentum down
+6.5%
Win rate 68.8% Excess -2.5%
458d
-4.1%
Win rate 38.5% Excess -6.2%
122d
+34%
Win rate 100% Excess +20%
53d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 205 historical days, 120-day forward avg gained 14.8%, win rate 92.7%, beat the market by 1.8%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 97,878 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.3% positive-return rate, and +2.90 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

22 times historically; 60-day forward avg +1.91%, win rate 52.4%, beating the market by -0.24 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

23 times historically; 60-day forward avg -0.11%, win rate 60.9%, beating the market by -1.82 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

24 times historically; 60-day forward avg +5.08%, win rate 70%, beating the market by +0.93 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.